Evaluation and Management of Idiopathic Erythrocytosis (Primary Polycythemia)

Diagnostic Indicators

Low serum erythropoietin (below the normal adult range of 10–30 mU/mL) together with elevated hemoglobin indicates autonomous red‑cell production independent of hypoxic signaling, thereby excluding secondary polycythemia. [1][2]
Persistent isolated erythrocytosis over several years without leukocytosis or thrombocytosis raises suspicion for an indolent myeloproliferative disorder but makes aggressive malignancy less likely. 3

Perform a complete blood count with reticulocyte count and a peripheral blood smear to confirm isolated erythrocytosis and assess red‑cell morphology. 2
Measure serum erythropoietin level to verify suppression; a markedly elevated level (>500 mU/mL) would indicate erythropoietin resistance, which is unlikely in this context. 1
Test for JAK2 V617F and JAK2 exon 12 mutations (and other myeloproliferative markers) to rule out polycythemia vera, even when white‑cell and platelet counts are normal. 1
Conduct iron studies, vitamin B12, and folate assays to exclude nutritional deficiencies that can mask true hemoglobin concentration. 2
Obtain arterial blood gas and oxygen saturation, and assess carboxyhemoglobin if carbon‑monoxide exposure is possible, to rule out occult hypoxemia. 1
Perform renal and abdominal imaging (ultrasound or CT) to screen for renal cell carcinoma, hepatic tumors, cystic disease, or renal‑artery stenosis that could produce ectopic erythropoietin. 1
Consider brain MRI when cerebellar hemangioblastoma or meningioma is clinically suspected. 1
Evaluate for right‑to‑left shunts with echocardiography and assess pulmonary function or sleep study if hypoventilation or obstructive sleep apnea is a concern. 1

In the absence of identified secondary causes or myeloproliferative disease, observe the patient with hemoglobin checks every 4–8 weeks initially, extending intervals if stability persists. 2
Re‑evaluate the complete blood count periodically to detect emergence of leukocytosis or thrombocytosis indicative of disease progression. 2

Phlebotomy is not indicated for patients with stable hemoglobin‑M disease or high‑oxygen‑affinity hemoglobinopathies, as the increased erythrocyte mass compensates for reduced oxygen delivery. 3
If idiopathic erythrocytosis is confirmed and hemoglobin exceeds 18 g/dL or symptoms develop, phlebotomy may be employed to keep hemoglobin below 16 g/dL (target hematocrit < 45 %) to lower thrombotic risk. 1
Exogenous erythropoietin therapy is contraindicated because endogenous production is already autonomous; such therapy increases thromboembolic risk by approximately 67 % (relative risk 1.67, 95 % CI 1.35–2.06). [1][2]
Low‑dose aspirin can be considered for thrombosis prophylaxis in the absence of contraindications, particularly when a JAK2 mutation is present. 1

Do not dismiss isolated erythrocytosis as a benign variation; low erythropoietin mandates thorough evaluation for occult malignancy and myeloproliferative neoplasms. 1
Do not initiate erythropoietin therapy or target hemoglobin levels > 12 g/dL, as this markedly raises mortality and thrombotic risk. [1][2]